Literature DB >> 24096626

Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment.

Luciana Grazziotin Rossato1, Vera Marisa Costa, Eliane Dallegrave, Marcelo Arbo, Renata Silva, Rita Ferreira, Francisco Amado, Ricardo Jorge Dinis-Oliveira, José Alberto Duarte, Maria de Lourdes Bastos, Carlos Palmeira, Fernando Remião.   

Abstract

Mitoxantrone (MTX) is a chemotherapeutic agent, which presents late irreversible cardiotoxicity. This work aims to highlight the mechanisms involved in the MTX-induced cardiotoxicity, namely the effects toward mitochondria using in vivo and in vitro studies. Male Wistar rats were treated with 3 cycles of 2.5 mg/kg MTX at day 0, 10, and 20. One treated group was euthanized on day 22 (MTX22) to evaluate the early MTX cardiac toxic effects, while the other was euthanized on day 48 (MTX48), to allow the evaluation of MTX late cardiac effects. Cardiac mitochondria isolated from 4 adult untreated rats were also used to evaluate in vitro the MTX (10 nM, 100 nM, and 1 μM) direct effects upon mitochondria functionality. Two rats of MTX48 died on day 35, and MTX treatment caused a reduction in relative body weight gain in both treated groups with no significant changes in water and food intake. Decreased levels of plasma total creatine kinase and CK-MB were detected in the MTX22 group, and increased plasma levels of lactate were seen in MTX48. Increased cardiac relative mass and microscopic changes were evident in both treated groups. Considering mitochondrial effects, for the first time, it was evidenced that MTX induced an increase in the complex IV and complex V activities in MTX22 group, while a decrease in the complex V activity was accompanied by the reduction in ATP content in the MTX48 rats. No alterations in mitochondria transmembrane potential were found in isolated mitochondria from MTX48 rats or in isolated mitochondria directly incubated with MTX. This study highlights the relevance of the cumulative MTX-induced in vivo mitochondriopathy to the MTX cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24096626     DOI: 10.1007/s12012-013-9230-2

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  15 in total

1.  Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.

Authors:  Sandipan Datta; Thomas Sears; Gino Cortopassi; Kevin Woolard; James M Angelastro
Journal:  Biomed Pharmacother       Date:  2020-12-08       Impact factor: 6.529

Review 2.  Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress.

Authors:  Jean C Bikomeye; Janée D Terwoord; Janine H Santos; Andreas M Beyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-05       Impact factor: 5.125

Review 3.  Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.

Authors:  Zahra Talebi; Alex Sparreboom; Susan I Colace
Journal:  Methods Mol Biol       Date:  2022

Review 4.  VDAC2 as a novel target for heart failure: Ca2+ at the sarcomere, mitochondria and SR.

Authors:  Paul Rosenberg
Journal:  Cell Calcium       Date:  2022-03-28       Impact factor: 4.690

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.

Authors:  Venkat Subramaniam; Gin Chuang; Huijing Xia; Brendan Burn; Jessica Bradley; Jerome L Maderdrut; David H Coy; Kurt J Varner
Journal:  Peptides       Date:  2017-07-15       Impact factor: 3.750

Review 6.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

7.  Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.

Authors:  Vera Marisa Costa; João Paulo Capela; Joana R Sousa; Rute P Eleutério; Patrícia R S Rodrigues; José Luís Dores-Sousa; Rui A Carvalho; Maria Lourdes Bastos; José Alberto Duarte; Fernando Remião; M Gabriela Almeida; Kurt J Varner; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-09-07       Impact factor: 5.153

8.  Mitoxantrone is More Toxic than Doxorubicin in SH-SY5Y Human Cells: A 'Chemobrain' In Vitro Study.

Authors:  Daniela Almeida; Rita Pinho; Verónica Correia; Jorge Soares; Maria de Lourdes Bastos; Félix Carvalho; João Paulo Capela; Vera Marisa Costa
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-05

9.  Inflammation as a Possible Trigger for Mitoxantrone-Induced Cardiotoxicity: An In Vivo Study in Adult and Infant Mice.

Authors:  Ana Reis-Mendes; José Luís Dores-Sousa; Ana Isabel Padrão; Margarida Duarte-Araújo; José Alberto Duarte; Vítor Seabra; Salomé Gonçalves-Monteiro; Fernando Remião; Félix Carvalho; Emília Sousa; Maria Lourdes Bastos; Vera Marisa Costa
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26

10.  Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells.

Authors:  Ana Reis-Mendes; Marisa Alves; Félix Carvalho; Fernando Remião; Maria Lourdes Bastos; Vera Marisa Costa
Journal:  Interdiscip Toxicol       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.